{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:12:08Z","timestamp":1788455528444,"version":"build-2803163510"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018693","name":"Horizon Europe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012818","name":"Community of Madrid","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["DTS15\/00171"],"award-info":[{"award-number":["DTS15\/00171"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["FIS2100989"],"award-info":[{"award-number":["FIS2100989"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["HORIZON-JU-GH-EDCTP3-2023-01"],"award-info":[{"award-number":["HORIZON-JU-GH-EDCTP3-2023-01"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CM20\/00205and CM23\/00257"],"award-info":[{"award-number":["CM20\/00205and CM23\/00257"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CD23\/00174"],"award-info":[{"award-number":["CD23\/00174"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009082","name":"Universidad Cat\u00f3lica de C\u00f3rdoba","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009082","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023961","name":"Centro de Investigaci\u00f3n Biotecnol\u00f3gica en Red de Enfermedades Infecciosas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023961","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.vaccine.2026.128764","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:07:52Z","timestamp":1780099672000},"page":"128764","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Oral immunization with virus-like particles elicits Ebola virus-specific humoral and cellular immune responses in mice"],"prefix":"10.1016","volume":"87","author":[{"given":"F\u00e1tima","family":"Lasala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Luczkowiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Labiod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzalo","family":"Rivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Octavio","family":"Arce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonor","family":"Kremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M.","family":"Casasnovas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Olal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Heung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Escudero-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Garc\u00eda-Bernalt Diego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9sar","family":"Mu\u00f1oz-Fontela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128764_bb0005","article-title":"Host\u2013pathogen interactions of emerging zoonotic viruses: bats, humans and filoviruses","volume":"68\u201369","author":"Hood","year":"2024","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.vaccine.2026.128764_bb0010","first-page":"363","article-title":"Ebolavirus and other filoviruses","volume":"315","author":"Gonzalez","year":"2007","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2026.128764_bb0015","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s00705-023-05834-2","article-title":"Renaming of genera Ebolavirus and Marburgvirus to Orthoebolavirus and Orthomarburgvirus, respectively, and introduction of binomial species names within family Filoviridae","volume":"168","author":"Biedenkopf","year":"2023","journal-title":"Arch Virol"},{"key":"10.1016\/j.vaccine.2026.128764_bb0020","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1056\/NEJMra1901594","article-title":"Ebola","volume":"382","author":"Feldmann","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128764_bb0025","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1056\/NEJMoa1504874","article-title":"Clinical management of Ebola virus disease in the United States and Europe","volume":"374","author":"Uyeki","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128764_bb0030","article-title":"Ebola RNA persistence in semen of Ebola virus disease survivors - preliminary report","author":"Deen","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128764_bb0035","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-021-03901-9","article-title":"Resurgence of Ebola virus in 2021 in Guinea suggests a new paradigm for outbreaks","author":"Keita","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2026.128764_bb0040","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1509773","article-title":"Molecular evidence of sexual transmission of Ebola virus","volume":"373","author":"Mate","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128764_bb0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003273","article-title":"Persistence of Ebola virus in semen among Ebola virus disease survivors in Sierra Leone: a cohort study of frequency, duration, and risk factors","volume":"18","author":"Thorson","year":"2021","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2026.128764_bb0050","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.coviro.2017.02.006","article-title":"Ebola virus persistence as a new focus in clinical research","volume":"23","author":"Caviness","year":"2017","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.vaccine.2026.128764_bb0055","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/nyas.14519","article-title":"Presence of Ebola virus in breast milk and risk of mother-to-child transmission: synthesis of evidence","volume":"1488","author":"Medina-Rivera","year":"2021","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.vaccine.2026.128764_bb0060","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1056\/NEJMoa1904387","article-title":"Ebola outbreak response in the DRC with rVSV-ZEBOV-GP ring vaccination","volume":"391","author":"Muyembe","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128764_bb0065","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0140-6736(15)61117-5","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial","volume":"386","author":"Henao-Restrepo","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2026.128764_bb0070","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1001\/jama.2016.4218","article-title":"Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia Ankara-vectored Ebola vaccines: a randomized clinical Trial","volume":"315","author":"Milligan","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2026.128764_bb0075","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.coi.2021.03.008","article-title":"Ebola virus disease: current vaccine solutions","volume":"71","author":"Tomori","year":"2021","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.vaccine.2026.128764_bb0080","doi-asserted-by":"crossref","first-page":"246","DOI":"10.4161\/gmic.24197","article-title":"Oral vaccines: directed safe passage to the front line of defense","volume":"4","author":"Zhu","year":"2013","journal-title":"Gut Microbes"},{"key":"10.1016\/j.vaccine.2026.128764_bb0085","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(10)60667-8","article-title":"Ebola haemorrhagic fever","volume":"377","author":"Feldmann","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2026.128764_bb0090","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1016\/j.vaccine.2004.11.070","article-title":"Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections","volume":"23","author":"Swenson","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128764_bb0095","doi-asserted-by":"crossref","first-page":"15889","DOI":"10.1073\/pnas.2237038100","article-title":"Ebola virus-like particles protect from lethal Ebola virus infection","volume":"100","author":"Warfield","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2026.128764_bb0100","doi-asserted-by":"crossref","first-page":"S574","DOI":"10.1093\/infdis\/jiy302","article-title":"Broad neutralizing activity against ebolaviruses lacking the mucin-like domain in convalescent plasma specimens from patients with Ebola virus disease","volume":"218","author":"Luczkowiak","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128764_bb0105","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.virusres.2015.12.019","article-title":"Specific neutralizing response in plasma from convalescent patients of Ebola Virus disease against the West Africa Makona variant of Ebola virus","volume":"213","author":"Luczkowiak","year":"2016","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2026.128764_bb0110","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1093\/infdis\/jiab634","article-title":"Neutralizing response against SARS-CoV-2 variants 8 months after BNT162b2 vaccination in naive and COVID-19\u2013convalescent individuals","volume":"225","author":"Luczkowiak","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128764_bb0115","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jviromet.2010.08.006","article-title":"Generation of VSV pseudotypes using recombinant \u0394G-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines","volume":"169","author":"Whitt","year":"2010","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2026.128764_bb0120","doi-asserted-by":"crossref","first-page":"4464","DOI":"10.1016\/j.vaccine.2020.04.034","article-title":"An effective CTL peptide vaccine for Ebola Zaire based on survivors\u2019 CD8+ targeting of a particular nucleocapsid protein epitope with potential implications for COVID-19 vaccine design","volume":"38","author":"Herst","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128764_bb0125","doi-asserted-by":"crossref","first-page":"10386","DOI":"10.1128\/JVI.00594-10","article-title":"Vector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primates","volume":"84","author":"Geisbert","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2026.128764_bb0130","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/nm1258","article-title":"Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses","volume":"11","author":"Jones","year":"2005","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2026.128764_bb0135","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/nature01876","article-title":"Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates","volume":"424","author":"Sullivan","year":"2003","journal-title":"Nature"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2026.128764_bb0140","doi-asserted-by":"crossref","first-page":"S421","DOI":"10.1086\/520612","article-title":"Filovirus-like particles produced in insect cells: immunogenicity and protection in rodents","volume":"196","author":"Warfield","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128764_bb0145","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01884-19","article-title":"A bivalent, spherical virus-like particle vaccine enhances breadth of immune responses against pathogenic Ebola viruses in rhesus macaques","volume":"94","author":"Singh","year":"2020","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2026.128764_bb0150","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S1473-3099(18)30602-9","article-title":"Interventions to improve oral vaccine performance: a systematic review and meta-analysis","volume":"19","author":"Church","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128764_bb0155","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0140-6736(87)90480-6","article-title":"Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation","volume":"1","author":"Levine","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2026.128764_bb0160","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1128\/CVI.00378-14","article-title":"Critical analysis of compositions and protective efficacies of oral killed cholera vaccines","volume":"21","author":"Kabir","year":"2014","journal-title":"Clin Vaccine Immunol CVI"},{"key":"10.1016\/j.vaccine.2026.128764_bb0165","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/nrmicro2129","article-title":"Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule","volume":"7","author":"Sullivan","year":"2009","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.vaccine.2026.128764_bb0170","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1073\/pnas.1502619112","article-title":"Human Ebola virus infection results in substantial immune activation","volume":"112","author":"McElroy","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2026.128764_bb0175","doi-asserted-by":"crossref","first-page":"10415","DOI":"10.1007\/s00253-015-7000-8","article-title":"The application of virus-like particles as vaccines and biological vehicles","volume":"99","author":"Yan","year":"2015","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1016\/j.vaccine.2026.128764_bb0180","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.1002\/jps.22724","article-title":"Biophysical characterization and conformational stability of Ebola and Marburg virus-like particles","volume":"100","author":"Hu","year":"2011","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.vaccine.2026.128764_bb0185","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1038\/nm.2866","article-title":"Large intestine-targeted, nanoparticle-releasing oral vaccine to control genitorectal viral infection","volume":"18","author":"Zhu","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2026.128764_bb0190","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41467-018-08265-9","article-title":"Efficient oral vaccination by bioengineering virus-like particles with protozoan surface proteins","volume":"10","author":"Serradell","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2026.128764_bb0195","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.837443","article-title":"A thermostable oral SARS-CoV-2 vaccine induces mucosal and protective immunity","volume":"13","author":"Bellier","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2026.128764_bb0200","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/nri1057","article-title":"Anatomical basis of tolerance and immunity to intestinal antigens","volume":"3","author":"Mowat","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2026.128764_bb0205","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-026-44944-0","article-title":"Oral immunization with filovirus-like particles partially protects IFNAR\u2212\/\u2212 mice against lethal Ebola virus challenge","volume":"16","author":"Escudero-P\u00e9rez","year":"2026","journal-title":"Sci Rep"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26005736?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26005736?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T06:46:24Z","timestamp":1783147584000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26005736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":41,"alternative-id":["S0264410X26005736"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128764","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral immunization with virus-like particles elicits Ebola virus-specific humoral and cellular immune responses in mice","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128764","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128764"}}